Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cadonilimab in Neoadjuvant Chemotherapy and Maintenance Therapy for Newly Diagnosed, High-risk, Locally Advanced Cervical Cancer :a Multi-center, Prospective, Single-arm Study(CNCMT)

NCT06714084 is registered in ClinicalTrials.gov with Hubei Cancer Hospital as lead sponsor.

NCT NCT06714084
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06714084 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cadonilimab in Neoadjuvant Chemotherapy and Maintenance Therapy for Newly Diagnosed, High-risk, Locally Advanced Cervical Cancer :a Multi-center, Prospective, Single-arm Study(CNCMT)
Lead sponsor
Hubei Cancer Hospital
Phase
Not applicable
Overall status
Enrolling by invitation
Start date
October 8, 2024
Completion date
December 31, 2026
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ctla4, locally advanced cervical cancer, pd1